369TiPPATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC). (23rd October 2018) - Loibl, S; Metzger, O; Mandrekar, S J; Mundhenke, C; Seiler, S; Valagussa, P; DeMichele, A; Lim, E; Tripathy, D; Winer, E P; Huang, C; Carey, L; et al.